Adlai Nortye Ltd. (ANL)
| Market Cap | 379.60M +491.3% |
| Revenue (ttm) | 5.00M |
| Net Income | -35.53M |
| EPS | -1.11 |
| Shares Out | 40.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 480,899 |
| Open | 10.58 |
| Previous Close | 10.60 |
| Day's Range | 8.54 - 11.35 |
| 52-Week Range | 0.88 - 17.25 |
| Beta | 1.11 |
| Analysts | Strong Buy |
| Price Target | 28.60 (+201.37%) |
| Earnings Date | Apr 10, 2026 |
About ANL
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RA... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ANL stock is "Strong Buy." The 12-month stock price target is $28.6, which is an increase of 201.37% from the latest price.
News
Cantor starts Adlai Nortye at Overweight, sees 180% upside
Cantor Fitzgerald initiated coverage of Adlai Nortye (ANL) with an Overweight rating without a price target The company has shifted focus to the RAS pathway in metastatic pancreatic ductal adenocarcin...
Adlai Nortye initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Adlai Nortye (ANL) with an Overweight rating.
Adlai Nortye Transcript: Jefferies Global Healthcare Conference 2026
Two RAS-targeted programs are advancing, with AN9025 in phase I and AN4035 ADC entering clinical studies in 2024. Intermittent dosing may widen the therapeutic window, and the ADC platform enables selective tumor targeting and rational combinations, especially in colorectal cancer.
Adlai Nortye initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Adlai Nortye (ANL) with an Outperform rating and $32 price target While the shares are up 770% year-to-date on a favorable read-through to AN9025 from Revolution…
Adlai Nortye initiated with a Buy at JonesResearch
JonesResearch analyst Boris Peaker initiated coverage of Adlai Nortye (ANL) with a Buy rating and $22 price target. Adlai had a recent recapitalization and refocus on pan-RAS(ON) inhibitors, which inc...
Adlai Nortye Registration statement: Registration filing
Adlai Nortye filed a registration statement on April 24, 2026, providing details about a securities offering with the SEC.
Adlai Nortye Registration statement: Registration filing
Adlai Nortye filed a registration statement on April 23, 2026, providing details about a securities offering with the SEC.
Adlai Nortye price target raised to $20 from $16 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Adlai Nortye (ANL) to $20 from $16 and keeps a Buy rating on the shares. The company’s lead asset,…
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the develop...
Adlai Nortye Ltd (ADR) trading resumes
10:11 EDT Adlai Nortye (ANL) Ltd (ADR) trading resumes
Adlai Nortye Ltd (ADR) trading halted, volatility trading pause
09:31 EDT Adlai Nortye (ANL) Ltd (ADR) trading halted, volatility trading pause
Adlai Nortye Annual report: Q4 2025
Adlai Nortye has published its Q4 2025 annual report on April 10, 2026.
Leerink bullish on Adlai Nortye, initiates with an Outperform
As previously reported, Leerink initiated coverage of Adlai Nortye (ANL) with an Outperform rating and $23 price target The firm says Adlai Nortye represents the next generation of Chinese biopharma,…
Adlai Nortye initiated with an Outperform at Leerink
Leerink initiated coverage of Adlai Nortye (ANL) with an Outperform rating and $23 price target
Adlai Nortye files to sell $600M of Class A ordinary shares
08:50 EDT Adlai Nortye (ANL) files to sell $600M of Class A ordinary shares
Adlai Nortye files to sell 64.62M Class A ordinary shares for holders
08:50 EDT Adlai Nortye (ANL) files to sell 64.62M Class A ordinary shares for holders
Adlai Nortye Registration statement: Registration Filing
Adlai Nortye filed a registration statement on March 10, 2026, providing details about a securities offering with the SEC.
Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic
As previously reported, H.C. Wainwright upgraded Adlai Nortye (ANL) to Buy from Neutral with a $16 price target after the company announced it dosed the first patient in it Phase…
Adlai Nortye upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Adlai Nortye (ANL) to Buy from Neutral with a $16 price target
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company foc...
Adlai Nortye prices 64.6M shares at $2.17 in private placement
Adlai Nortye (ANL) entered into securities purchase agreements for a private investment in public equity financing that is expected to result in gross proceeds of approximately $140M, before deducting...
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.
Adlai Nortye Ltd (ADR) trading resumes
09:44 EST Adlai Nortye (ANL) Ltd (ADR) trading resumes
Adlai Nortye Ltd (ADR) trading halted, volatility trading pause
09:39 EST Adlai Nortye (ANL) Ltd (ADR) trading halted, volatility trading pause
Adlai Nortye initiated with a Buy at Lucid Capital
Lucid Capital analyst Christopher Liu initiated coverage of Adlai Nortye (ANL) with a Buy rating and $11 price target Adlai is a clinical-stage biotechnology company focused on developing novel oncolo...